Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenretinide Mucoadhesive System in Premalignant Oral Intraepithelial Neoplasia
NCT07149220Phase 1Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Oct 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fenretinide in Oral intraepithelial neoplasia (OIN) (2 arms), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoints: Histopathologic grade at 6 weeks, Clinical size at 6 weeks and 1 more. Started Oct 2025; status: completed.
02
Drugs
fenretinide
03
Conditions
Oral intraepithelial neoplasia (OIN)
Beyond the preview
Go deeper on NCT07149220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07149220.